Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €51.35 EUR
Change Today -0.71 / -1.37%
Volume 0.0
0PT On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 2:29 PM 08/31/15 All times are local (Market data is delayed by at least 15 minutes).

prothena corp plc (0PT) Snapshot

Open
€52.06
Previous Close
€52.07
Day High
€52.46
Day Low
€51.34
52 Week High
07/23/15 - €63.13
52 Week Low
10/13/14 - €13.47
Market Cap
1.6B
Average Volume 10 Days
20.1
EPS TTM
--
Shares Outstanding
31.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for PROTHENA CORP PLC (0PT)

Related News

No related news articles were found.

prothena corp plc (0PT) Related Businessweek News

No Related Businessweek News Found

prothena corp plc (0PT) Details

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on the discovery, development, and commercialization of protein immunotherapy programs for the treatment of diseases that involve amyloid or cell adhesion in Ireland. The company’s product pipeline includes NEOD001, a product candidate that is in Phase III clinical trials to treat patients with AL amyloidosis, as well as is in Phase I/II clinical trials for AL amyloidosis and persistent organ dysfunction. It is also developing PRX002 that is in Phase I clinical trials for the treatment of Parkinson’s disease and other synucleinopathies; and PRX003, a monoclonal antibody for psoriasis and other inflammatory diseases. The company has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein. Prothena Corporation plc was incorporated in 2012 and is headquartered in Dublin, Ireland.

46 Employees
Last Reported Date: 03/13/15
Founded in 2012

prothena corp plc (0PT) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $491.7K
Chief Financial Officer
Total Annual Compensation: $338.3K
Chief Scientific Officer and Head of Research...
Total Annual Compensation: $398.3K
Chief Medical Officer
Total Annual Compensation: $348.5K
Chief Legal Officer
Total Annual Compensation: $217.9K
Compensation as of Fiscal Year 2014.

prothena corp plc (0PT) Key Developments

Prothena Corporation plc Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015; Provides Earnings Guidance for the Year 2015

Prothena Corporation plc reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company's total revenue was $278,000 compared to $15,121,000 a year ago. Loss from operations was $18,035,000 compared to income from operations of $1,569,000 a year ago. Loss before income taxes was $18,082,000 compared to income before income taxes of $1,586,000 a year ago. Net loss was $18,277,000 compared to net income of $1,290,000 a year ago. Net loss per diluted share attributable to holders of ordinary shares was $0.59 compared to income of $0.06 a year ago. Net cash used in operating activities was $11.1 million and $25.9 million for first six months of 2015. For the six months, the company's total revenue was $871,000 compared to $47,355,000 a year ago. Loss from operations was $33,064,000 compared to income from operations of $19,588,000 a year ago. Loss before income taxes was $33,018,000 compared to income before income taxes of $19,589,000 a year ago. Net loss was $33,479,000 compared to net income of $19,142,000 a year ago. Net loss per diluted share attributable to holders of ordinary shares was $1.15 compared to income of $0.83 a year ago. The decrease in total revenue was primarily due to $15.0 million and $47.1 million in collaboration revenue recognized in relation to the PRX002 collaboration with Roche in the second quarter and first six months of 2014, compared to $0.3 million and $0.9 million in collaboration revenue recognized in the second quarter and first six months of 2015, respectively. The company continues to expect the full year 2015 net cash burn from operating and investing activities to be $66 to $72 million, ending the year with approximately $356 million in cash. The estimated full year 2015 net cash burn from operating and investing activities is primarily driven by an estimated net loss of $77 to $83 million, which includes an estimated $9 million of non-cash share-based compensation expense.

Prothena Corporation plc Presents at Wedbush PacGrow Healthcare Conference 2015, Aug-12-2015 01:20 PM

Prothena Corporation plc Presents at Wedbush PacGrow Healthcare Conference 2015, Aug-12-2015 01:20 PM. Venue: Le Parker Meridian, 119 West 56th Street, New York, NY 10019, United States.

Prothena Corporation plc Appoints Anders Härfstrand to its Board of Directors

Prothena Corporation plc announced the appointment of Anders Härfstrand, MD, PhD, to its Board of Directors. Anders' wealth of strategic expertise leading both entrepreneurial and large commercial organizations will serve as a valuable asset as continue development of pipeline of potential therapies, and in particular as move NEOD001 towards commercialization. Dr. Härfstrand was most recently the CEO of BBB Therapeutics BV.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
0PT:GR €51.35 EUR -0.71

0PT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 0PT.
View Industry Companies
 

Industry Analysis

0PT

Industry Average

Valuation 0PT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 419.4x
Price/Book 4.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 335.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PROTHENA CORP PLC, please visit www.prothena.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.